Pneumococcal conjugate vaccine and pneumococcal common protein vaccines

Vaccines

Volumn , Issue , 2008, Pages 531-567

  Black, Steven ^a   Eskola, Juhani ^b   Whitney, Cynthia ^c   Shinefield, Henry ^d  

^a STANFORD UNIVERSITY   (United States)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85159028267     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3611-1.50027-1     Document Type: Chapter

References (483)

1. GT Rijkers, EAM Sanders, MA Breukels and BJ Zegers (1996) Reponsiveness of infants to capsular polysaccharides: Implications for vaccine development. Rev Med Microbiol 7(1), 3-12.
2. RM Douglas, JC Paton, SJ Duncan and DJ Hansman (1983) Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 148(1), 131-137.
3. M Leinonen, A Sakkinen, R Kalliokoski, et al. (1986) Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in pre-school age children. Pediatr Infect Dis 5(1), 39-44.
4. D Gibb, V Spoulou, A Giacomelli, et al. (1995) Antibody responses to Haemophilus influenzae type b and Streptococcus pneumoniae vaccines in children with human immunodeficiency virus infection. Pediatr Infect Dis J 14(2), 129-135.
5. PJ Carson, RL Schut, ML Simpson, et al. (1995) Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients. J Infect Dis 172(2), 340-345.
6. J Rautonen, MA Siimes, U Lundstrom, et al. (1986) Vaccination of children during treatment for leukemia. Acta Paediatr Scand 75(4), 579-585.
7. G Grimfors, M Bjorkholm, L Hammarstrom, et al. (1989) Type-specific anti-pneumococcal antibody subclass response to vaccination after splenectomy with special reference to lymphoma patients. Eur J Haematol 43(5), 404-410.
8. T Parkkali, H Kayhty, T Ruutu, et al. (1996) A comparison of early and late vaccination with Haemophilus influenzae type b conjugate and pneumococcal polysaccharide vaccines after allogeneic BMT. Bone Marrow Transplant 18(5), 961-967.
9. T Parkkali, M Vakevainen, H Kayhty, et al. (2001) Opsonophagocytic activity against Streptococcus pneumoniae type 19F in allogeneic BMT recipients before and after vaccination with pneumococcal polysaccharide vaccine. Bone Marrow Transplant 27(2), 207-211.
10. C MacLeod, R Hodges, M Heidelberger, et al. (1945) Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med 82 445-465.
11. GP van den Dobbelsteen and EP van Rees (1995) Mucosal immune responses to pneumococcal polysaccharides: implications for vaccination. Trends Microbiol 3(4), 155-159.
12. E Herva, J Luotonen, M Timonen, et al. (1980) The effect of polyvalent pneumococcal polysaccharide vaccine on nasopharyngeal and nasal carriage of Streptococcus pneumoniae. Scand J Infect Dis 12(2), 97-100.
13. PH Mäkelä, M Sibakov, E Herva, et al. (1980) Pneumococcal vaccine and otitis media. Lancet 2(8194), 547-551.
14. PH Mäkelä, P Karma, M Sipila, et al. (1983) Possibilities of preventing otitis media by vaccination. Scand J Infect Dis Suppl 39 34-38.
15. Prevention of pneumococcal disease recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 46(RR-8), 1-24.
16. BG Williams, E Gouws, C Boschi-Pinto, et al. (2002) Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2(1), 25-32.
17. B Greenwood (1999) The epidemiology of pneumococcal infection in children in the developing world. Philos Trans R Soc Lond B Biol Sci 354(1384), 777-785.
18. CG Whitney, MM Farley, J Hadler, et al. (2000) Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 343(26), 1917-1924.
19. SE Beekmann, KP Heilmann, SS Richter, et al. (2005) Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002–2003. Results of the multinational GRASP Surveillance Program. Int J Antimicrob Agents 25(2), 148-156.
20. S Black, H Shinefield, B Fireman, et al. (2000) Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19(3), 187-195.
21. KP Klugman, SA Madhi, RE Huebner, et al. (2003) A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349(14), 1341-1348.
22. R Prymula, P Peeters, V Chrobok, et al. (2006) Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 367(9512), 740-748.
23. DE Briles, S Hollingshead, A Brooks-Walter, et al. (2000) The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine 18(16), 1707-1711.
24. GB Lesinski, SL Smithson, N Srivastava, et al. (2001) A DNA vaccine encoding a peptide mimic of Streptococcus pneumoniae serotype 4 capsular polysaccharide induces specific anti-carbohydrate antibodies in Balb/c mice. Vaccine 19(13–14), 1717-1726.
25. AR Nayak, SA Tinge, RC Tart, et al. (1998) A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae. Infect Immun 66(8), 3744-3751.
26. RM Buchanan, DE Briles, BP Arulanandam, et al. (2001) IL-12-mediated increases in protection elicited by pneumococcal and meningococcal conjugate vaccines. Vaccine 19(15–16), 2020-2028.
27. RS Chu, T McCool, NS Greenspan, et al. (2000) CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies. Infect Immun 68(3), 1450-1456.
28. P Dullforce, DC Sutton and AW Heath (1998) Enhancement of T cell-independent immune responses in vivo by CD40 antibodies. Nat Med 4(1), 88-91.
29. H Jakobsen, S Bjarnarson, G Del Giudice, et al. (2002) Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-Labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice. Infect Immun 70(3), 1443-1452.
30. JY Seo, SY Seong, BY Ahn, et al. (2002) Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in microspheres. Infect Immun 70(3), 1143-1149.
31. BP Arulanandam, JM Lynch, DE Briles, et al. (2001) Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun 69(11), 6718-6724.
32. H Jakobsen, E Saeland, S Gizurarson, et al. (1999) Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections. Infect Immun 67(8), 4128-4133.
33. W Goebel and O Avery (1929) Chemo-immunological studies on conjugated carbohydrate-proteins. I. The syntehsis of r-aminophenol β-glucoside, r-aminophenol β-lactoside and their coupling with serum globulin. J Exp Med 50 521-531.
34. O Avery and W Goebel (1929) Chemo-immunological studies on conjugated carbohydrate-proteins. II. Immunological specificity of synthetic sugar-protein antigen. J Exp Med 50 533-550.
35. P Anderson (1983) Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM197. Infect Immun 39(1), 233-238.
36. R Schneerson, O Barrera, A Sutton and JB Robbins (1980) Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 152(2), 361-376.
37. P Richmond, R Borrow, E Miller, et al. (1999) Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 179(6), 1569-1572.
38. C Chu, R Schneerson, JB Robbins and SC Rastogi (1983) Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun 40(1), 245-256.
39. AD Magee and J Yother (2001) Requirement for capsule in colonization by Streptococcus pneumoniae. Infect Immun 69(6), 3755-3761.
40. DA Watson, DM Musher and J Verhoef (1995) Pneumococcal virulence factors and host immune responses to them. Eur J Clin Microbiol Infect Dis 14(6), 479-490.
41. Y Mizrachi Nebenzahl, N Porat, S Lifshitz, et al. (2004) Virulence of Streptococcus pneumoniae may be determined independently of capsular polysaccharide. FEMS Microbiol Lett 233(1), 147-152.
42. M Martin, JH Turco, ME Zegans, et al. (2003) An outbreak of conjunctivitis due to atypical Streptococcus pneumoniae. N Engl J Med 348(12), 1112-1121.
43. DA Watson and DM Musher (1990) Interruption of capsule production in Streptococcus pneumonia serotype 3 by insertion of transposon Tn916. Infect Immun 58(9), 3135-3138.
44. E AlonsoDeVelasco, AF Verheul, J Verhoef and H Snippe (1995) Streptococcus pneumoniae: virulence factors, pathogenesis and vaccines. Microbiol Rev 59(4), 591-603.
45. JT Jokinen, H Ahman, TM Kilpi, et al. (2004) Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. J Infect Dis 190(3), 545-550.
46. R Dagan, N Givon-Lavi, D Fraser, et al. (2005) Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis 192(3), 367-376.
47. Preventing pneumococcal disease among infants and young children (2000) Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 49(RR-9), 1-35.
48. KA Robinson, W Baughman, G Rothrock, et al. (2001) Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: Opportunities for prevention in the conjugate vaccine era. JAMA 285(13), 1729-1735.
49. G Bjornson, D Scheifele, F Binder and D Talling (2000) Population-based incidence rate of invasive pneumococcal infection in children: Vancouver, 1994–1998. Can Commun Dis Rep 26(18), 149-151; discussion 151–142.
50. R von Kries, A Siedler, HJ Schmitt and RR Reinert (2000) Proportion of invasive pneumococcal infections in German children preventable by pneumococcal conjugate vaccines. Clin Infect Dis 31(2), 482-487.
51. J Eskola, AK Takala, E Kela, et al. (1992) Epidemiology of invasive pneumococcal infections in children in Finland. JAMA 268(23), 3323-3327.
52. WP Hausdorff, J Bryant, PR Paradiso and GR Siber (2000) Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 30(1), 100-121.
53. E Miller, P Waight, A Efstratiou, et al. (2000) Epidemiology of invasive and other pneumococcal disease in children in England and Wales 1996–1998. Acta Paediatr Suppl 89(435), 11-16.
54. WP Hausdorff, G Siber and PR Paradiso (2001) Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet 357(9260), 950-952.
55. C Ziebold, R von Kries, A Siedler and HJ Schmitt (2000) Epidemiology of pneumococcal disease in children in Germany. Acta Paediatr Suppl 89(435), 17-21.
56. M Eriksson, B Henriques and K Ekdahl (2000) Epidemiology of pneumococcal infections in Swedish children. Acta Paediatr Suppl 89(435), 35-39.
57. D Scheifele, S Halperin, L Pelletier and J Talbot (2000) Invasive pneumococcal infections in Canadian children, 1991–1998: implications for new vaccination strategies. Canadian Paediatric Society/Laboratory Centre for Disease Control Immunization Monitoring Program, Active (IMPACT). Clin Infect Dis 31(1), 58-64.
58. SL Kaplan, EO Jr, ER Wald, et al. (2002) Six year multicenter surveillance of invasive pneumococcal infections in children. Pediatr Infect Dis J 21(2), 141-147.
59. OS Levine, M Farley, LH Harrison, et al. (1999) Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatrics 103(3), E28.
60. P Ispahani, RC Slack, FE Donald, et al. (2004) Twenty year surveillance of invasive pneumococcal disease in Nottingham: serogroups responsible and implications for immunisation. Arch Dis Child 89(8), 757-762.
61. A Schuchat, K Robinson, JD Wenger, et al. (1997) Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 337(14), 970-976.
62. ER Alpern, EA Alessandrini, KL McGowan, et al. (2001) Serotype prevalence of occult pneumococcal bacteremia. Pediatrics 108(2), E23.
63. KL O'Brien, J Shaw, R Weatherholtz, et al. (2004) Epidemiology of invasive Streptococcus pneumoniae among Navajo children in the era before use of conjugate pneumococcal vaccines, 1989–1996. Am J Epidemiol 160(3), 270-278.
64. A Melegaro, WJ Edmunds, R Pebody, et al. (2006) The current burden of pneumococcal disease in England and Wales. J Infect 52(1), 37-48.
65. SM Schappert and CW Burt (2006) Ambulatory care visits to physician offices, hospital outpatient departments and emergency departments: United States, 2001–02. Vital Health Stat 13(159), 1-66.
66. J Bondy, S Berman, J Glazner and D Lezotte (2000) Direct expenditures related to otitis media diagnoses: extrapolations from a pediatric medicaid cohort. Pediatrics 105(6), E72.
67. SL Block, J Hedrick, CJ Harrison, et al. (2004) Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J 23(9), 829-833.
68. CD Bluestone, JS Stephenson and LM Martin (1992) Ten-year review of otitis media pathogens. Pediatr Infect Dis J 11(8 Suppl), S7-S11.
69. T Kilpi, E Herva, T Kaijalainen, et al. (2001) Bacteriology of acute otitis media in a cohort of Finnish children followed for the first two years of life. Pediatr Infect Dis J 20(7), 654-662.
70. AA Palmu, JT Jokinen, T Kaijalainen, et al. (2005) Association of clinical signs and symptoms with pneumococcal acute otitis media by serotype–implications for vaccine effect. Clin Infect Dis 40(1), 52-57.
71. HB Konradsen and MS Kaltoft (2002) Invasive pneumococcal infections in Denmark from 1995 to 1999: epidemiology, serotypes and resistance. Clin Diagn Lab Immunol 9(2), 358-365.
72. K Sleeman, K Knox, R George, et al. (2001) Invasive pneumococcal disease in England and Wales: vaccination implications. J Infect Dis 183(2), 239-246.
73. JP Nuorti, JC Butler, L Gelling, et al. (2000) Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 132(3), 182-190.
74. AK Takala, J Jero, E Kela, et al. (1995) Risk factors for primary invasive pneumococcal disease among children in Finland. JAMA 273(11), 859-864.
75. SB Black, HR Shinefield, S Ling, et al. (2002) Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 21(9), 810-815.
76. VL Krause, SJ Reid and A Merianos (2000) Invasive pneumococcal disease in the Northern Territory of Australia, 1994–1998. Med J Aust 173(Suppl), S27-S31.
77. PB McIntyre and TM Nolan (2000) Conjugate pneumococcal vaccines for non-indigenous children in Australia. Med J Aust 173(Suppl), S54-S57.
78. R Dagan, D Engelhard, E Piccard and D Englehard (1992) Epidemiology of invasive childhood pneumococcal infections in Israel. The Israeli Pediatric Bacteremia and Meningitis Group. JAMA 268(23), 3328-3332.
79. D Fraser, N Givon-Lavi, N Bilenko and R Dagan (2001) A decade (1989–1998) of pediatric invasive pneumococcal disease in 2 populations residing in 1 geographic location: implications for vaccine choice. Clin Infect Dis 33(4), 421-427.
80. ED Barnett, SI Pelton, HJ Cabral, et al. (1999) Immune response to pneumococcal conjugate and polysaccharide vaccines in otitis-prone and otitis-free children. Clin Infect Dis 29(1), 191-192.
81. J Kolberg, EA Hoiby, A Aase, et al. (2000) Streptococcus pneumoniae heat shock protein 70 does not induce human antibody responses during infection. FEMS Immunol Med Microbiol 29(4), 289-294.
82. M Watson, P Roche, K Bayley, et al. (2004) Laboratory surveillance of invasive pneumococcal disease in Australia, 2003 predicting the future impact of the universal childhood conjugate vaccine program. Commun Dis Intell 28(4), 455-464.
83. WP Hausdorff, G Yothers, R Dagan, et al. (2002) Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr Infect Dis J 21(11), 1008-1016.
84. M Hortal, G Algorta, I Bianchi, et al. (1997) Capsular type distribution and susceptibility to antibiotics of Streptococcus pneumoniae clinical strains isolated from Uruguayan children with systemic infections. Pneumococcus Study Group. Microb Drug Resist 3(2), 159-163.
85. KL O'Brien, MI Walters, J Sellman, et al. (2000) Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. Clin Infect Dis 30(5), 784-789.
86. TR Talbot, KA Poehling, TV Hartert, et al. (2005) Seasonality of invasive pneumococcal disease: temporal relation to documented influenza and respiratory syncytial viral circulation. Am J Med 118(3), 285-291.
87. J Reefhuis, MA Honein, CG Whitney, et al. (2003) Risk of bacterial meningitis in children with cochlear implants. N Engl J Med 349(5), 435-445.
88. SA Madhi, K Petersen, A Madhi, et al. (2000) Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr Infect Dis J 19(12), 1141-1147.
89. SK Obaro (2000) Prospects for pneumococcal vaccination in African children. Acta Trop 75(2), 141-153.
90. CL Coles, R Kanungo, L Rahmathullah, et al. (2001) Pneumococcal nasopharyngeal colonization in young South Indian infants. Pediatr Infect Dis J 20(3), 289-295.
91. MM Levine, R Lagos, OS Levine, et al. (1998) Epidemiology of invasive pneumococcal infections in infants and young children in Metropolitan Santiago, Chile, a newly industrializing country. Pediatr Infect Dis J 17(4), 287-293.
92. A Jain, S Jain and V Gant (1995) Should patients positive for HIV infection receive pneumococcal vaccine. BMJ 310(6986), 1060-1062.
93. MS Dworkin, JW Ward, DL Hanson, et al. (2001) Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors and impact of vaccination. Clin Infect Dis 32(5), 794-800.
94. GA Poland (2001) The prevention of pneumococcal disease by vaccines: promises and challenges. Infect Dis Clin North Am 15(1), 97-122.
95. GD Overturf (2003) Indications for the immunological evaluation of patients with meningitis. Clin Infect Dis 36(2), 189-194.
96. ED Barnett, JO Klein, SI Pelton and LM Luginbuhl (1992) Otitis media in children born to human immunodeficiency virus-infected mothers. Pediatr Infect Dis J 11(5), 360-364.
97. BL Flannery, RT Heffernan, LH Harrison, et al. (2006) Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Annals Int Med 144 1-9.
98. I Grau, R Pallares, F Tubau, et al. (2005) Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 165(13), 1533-1540.
99. N Jones, R Huebner, M Khoosal, et al. (1998) The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. Aids 12(16), 2177-2184.
100. AS Karstaedt, M Khoosal and HH Crewe-Brown (2000) Pneumococcal bacteremia during a decade in children in Soweto, South Africa. Pediatr Infect Dis J 19(5), 454-457.
101. L Vernacchio, EJ Neufeld, K MacDonald, et al. (1998) Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr 133(2), 275-278.
102. FM Gill, LA Sleeper, SJ Weiner, et al. (1995) Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood 86(2), 776-783.
103. HS Zarkowsky, D Gallagher, FM Gill, et al. (1986) Bacteremia in sickle hemoglobinopathies. J Pediatr 109(4), 579-585.
104. ME Kizito, E Mworozi, C Ndugwa and GR Serjeant (2007) Bacteraemia in homozygous sickle cell disease in Africa: is pneumococcal prophylaxis justified? Arch. Dis. Child 92 21-33.
105. FE Babl, SI Pelton, S Theodore and JO Klein (2001) Constancy of distribution of serogroups of invasive pneumococcal isolates among children: experience during 4 decades. Clin Infect Dis 32(8), 1155-1161.
106. KL O'Brien, AJ Swift, JA Winkelstein, et al. (2000) Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group. Pediatrics 106(5), 965-972.
107. TV Adamkiewicz, S Sarnaik, GR Buchanan, et al. (2003) Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance and 23-valent pneumococcal polysaccharide vaccination. J Pediatr 143(4), 438-444.
108. GE Schutze, EO Mason Jr, WJ Barson, et al. (2002) Invasive pneumococcal infections in children with asplenia. Pediatr Infect Dis J 21(4), 278-282.
109. P McIntyre and JC Craig (1998) Prevention of serious bacterial infection in children with nephrotic syndrome. J Paediatr Child Health 34(4), 314-317.
110. EC Guinan, DC Molrine, JH Antin, et al. (1994) Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation 57(5), 677-684.
111. GE Schutze, EO Mason Jr, ER Wald, et al. (2001) Pneumococcal infections in children after transplantation. Clin Infect Dis 33(1), 16-21.
112. L Tran, D Hebert, A Dipchand, et al. (2005) Invasive pneumococcal disease in pediatric organ transplant recipients: a high-risk population. Pediatr Transplant 9(2), 183-186.
113. DC Molrine, S George, N Tarbell, et al. (1995) Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease. Ann Intern Med 123(11), 828-834.
114. R Mato, IS Sanches, C Simas, et al. (2005) Natural history of drug-resistant clones of Streptococcus pneumoniae colonizing healthy children in Portugal. Microb Drug Resist 11(4), 309-322.
115. N Michel, M Watson, F Baumann, et al. (2005) Distribution of Streptococcus pneumoniae serotypes responsible for penicillin resistance and the potential role of new conjugate vaccines in New Caledonia. J Clin Microbiol 43(12), 6060-6063.
116. M Hussain, A Melegaro, RG Pebody, et al. (2005) A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting. Epidemiol Infect 133(5), 891-898.
117. A Al-Mazrou, K Twum-Danso, F Al Zamil and A Kambal (2005) Streptococcus pneumoniae serotypes/serogroups causing invasive disease in Riyadh, Saudi Arabia: extent of coverage by pneumococcal vaccines. Ann Saudi Med 25(2), 94-99.
118. A Arguedas, R Dagan, S Guevara, et al. (2005) Middle ear fluid Streptococcus pneumoniae serotype distribution in Costa Rican children with otitis media. Pediatr Infect Dis J 24(7), 631-634.
119. I Serrano, J Melo-Cristino, JA Carrico and M Ramirez (2005) Characterization of the genetic lineages responsible for pneumococcal invasive disease in Portugal. J Clin Microbiol 43(4), 1706-1715.
120. MA Mufson and RJ Stanek (2004) Epidemiology of invasive Streptococcus pneumoniae infections and vaccine implications among children in a West Virginia community, 1978–2003. Pediatr Infect Dis J 23(8), 779-781.
121. I Serrano, M Ramirez and J Melo-Cristino (2004) Invasive Streptococcus pneumoniae from Portugal: implications for vaccination and antimicrobial therapy. Clin Microbiol Infect 10(7), 652-656.
122. A Malfroot, J Verhaegen, JM Dubru, et al. (2004) A cross-sectional survey of the prevalence of Streptococcus pneumoniae nasopharyngeal carriage in Belgian infants attending day care centres. Clin Microbiol Infect 10(9), 797-803.
123. R Prymula, J Motlova and P Kriz (2004) Comparison of Streptococcus pneumoniae serotypes causing acute otitis media & invasive disease in young children in the Czech Republic. Indian J Med Res 119(Suppl), 168-170.
124. D McGregor, M Barton, S Thomas and CD Christie (2004) Invasive pneumococcal disease in Jamaican children. Ann Trop Paediatr 24(1), 33-40.
125. S Esposito, DV Madore, S Gironi, et al. (2003) Theoretic coverage of heptavalent pneumococcal conjugate vaccine in the prevention of community-acquired pneumonia in children in Italy. Vaccine 21(21–22), 2704-2707.
126. SL Block, J Hedrick, CJ Harrison, et al. (2002) Pneumococcal serotypes from acute otitis media in rural Kentucky. Pediatr Infect Dis J 21(9), 859-865.
127. C Doit, C Loukil, P Geslin and E Bingen (2002) Phenotypic and genetic diversity of invasive pneumococcal isolates recovered from French children. J Clin Microbiol 40(8), 2994-2998.
128. P Marchisio, S Esposito, GC Schito, et al. (2002) Nasopharyngeal carriage of Streptococcus pneumoniae in healthy children: implications for the use of heptavalent pneumococcal conjugate vaccine. Emerg Infect Dis 8(5), 479-484.
129. S Soewignjo, BD Gessner, A Sutanto, et al. (2001) Streptococcus pneumoniae nasopharyngeal carriage prevalence, serotype distribution and resistance patterns among children on Lombok Island, Indonesia. Clin Infect Dis 32(7), 1039-1043.
130. ML Joloba, A Windau, S Bajaksouzian, et al. (2001) Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media. Clin Infect Dis 33(9), 1489-1494.
131. DH Sniadack, B Schwartz, H Lipman, et al. (1995) Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children–implications for vaccine strategies. Pediatr Infect Dis J 14(6), 503-510.
132. GS Giebink, JD Meier, MK Quartey, et al. (1996) Immunogenicity and efficacy of Streptococcus pneumoniae polysaccharide-protein conjugate vaccines against homologous and heterologous serotypes in the chinchilla otitis media model. J Infect Dis 173(1), 119-127.
133. R Dagan, N Givon-Lavi, O Zamir and D Fraser (2003) Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr Infect Dis J 22(6), 532-540.
134. M Davidson, AJ Parkinson, LR Bulkow, et al. (1994) The epidemiology of invasive pneumococcal disease in Alaska, 1986–1990—ethnic differences and opportunities for prevention. J Infect Dis 170(2), 368-376.
135. WP Hausdorff, J Bryant, C Kloek, et al. (2000) The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis 30(1), 122-140.
136. A Fenoll, I Jado, D Vicioso, et al. (2000) Streptococcus pneumoniae in children in Spain: 1990–1999. Acta Paediatr Suppl 89(435), 44-50.
137. N Zeuthen Kaltoft and HB Konradsen (2000) Epidemiology of invasive pneumococcal infections in children aged 0–6 years in Denmark: a 19-year nationwide surveillance study. Acta Paediatr Suppl 89(435), 3-10.
138. WP Hausdorff, DR Feikin and KP Klugman (2005) Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 5(2), 83-93.
139. TB Hyde, K Gay, DS Stephens, et al. (2001) Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 286(15), 1857-1862.
140. DJ Diekema, AB Brueggemann and GV Doern (2000) Antimicrobial-drug use and changes in resistance in Streptococcus pneumoniae. Emerg Infect Dis 6(5), 552-556.
141. C Garcia-Rey, L Aguilar, F Baquero, et al. (2002) Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. J Clin Microbiol 40(1), 159-164.
142. GV Doern, KP Heilmann, HK Huynh, et al. (2001) Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999–2000, including a comparison of resistance rates since 1994–1995. Antimicrob Agents Chemother 45(6), 1721-1729.
143. LA Herzenberg and T Tokuhisa (1982) Epitope-specific regulation. I. Carrier-specific induction of suppression for IgG anti-hapten antibody responses. J Exp Med 155(6), 1730-1740.
144. X Renjifo, S Wolf, PP Pastoret, et al. (1998) Carrier-induced, hapten-specific suppression: a problem of antigen presentation. J Immunol 161(2), 702-706.
145. R Dagan, J Eskola, C Leclerc and O Leroy (1998) Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun 66(5), 2093-2098.
146. Wyeth Pharmaceuticals Inc. Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM 197 Protein) Prevnar package insert.
147. J Kuo, M Douglas, HK Ree and AA Lindberg (1995) Characterization of a recombinant pneumolysin and its use as a protein carrier for pneumococcal type 18C conjugate vaccines. Infect Immun 63(7), 2706-2713.
148. ST Test, J Mitsuyoshi, CC Connolly and AH Lucas (2001) Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide. Infect Immun 69(5), 3031-3040.
149. F Ahmed, MC Steinhoff, MC Rodriguez-Barradas, et al. (1996) Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J Infect Dis 173(1), 83-90.
150. DC Powers, EL Anderson, K Lottenbach and CM Mink (1996) Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis 173(4), 1014-1018.
151. GR Siber, C Thompson, GR Reid, et al. (1992) Evaluation of bacterial polysaccharide immune globulin for the treatment or prevention of Haemophilus influenzae type b and pneumococcal disease. J Infect Dis 165(Suppl 1), S129-S133.
152. PA Shurin, JM Rehmus, CE Johnson, et al. (1993) Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children. J Pediatr 123(5), 801-810.
153. DS Fedson, DM Musher and J Eskola (2003) Pneumococcal vaccine. SA Plotkin, WA Orenstein (Eds) Vaccines 4th ed. Philadelphia: WB Saunders
154. M Koskela, M Harris and GS Giebink (1992) Enzyme immunoassay for detection of immunoglobulin G (IgG), IgM and IgA antibodies against type 6B pneumococcal capsular polysaccharide and cell wall C polysaccharide in chinchilla serum. J Clin Microbiol 30(6), 1485-1490.
155. A Soininen, I Seppala, T Wuorimaa and H Kayhty (1998) Assignment of immunoglobulin G1 and G2 concentrations to pneumococcal capsular polysaccharides 3, 6B, 14, 19F and 23F in pneumococcal reference serum 89-SF. Clin Diagn Lab Immunol 5(4), 561-566.
156. SA Quataert, CS Kirch, LJ Wiedl, et al. (1995) Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol 2(5), 590-597.
157. NF Concepcion and CE Frasch (2001) Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 8(2), 266-272.
158. CE Frasch and NF Concepcion (2000) Specificity of human antibodies reactive with pneumococcal C polysaccharide. Infect Immun 68(4), 2333-2337.
159. M Koskela (1987) Serum antibodies to pneumococcal C polysaccharide in children: response to acute pneumococcal otitis media or to vaccination. Pediatr Infect Dis J 6(6), 519-526.
160. CM Wernette, CE Frasch, D Madore, et al. (2003) Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 10(4), 514-519.
161. A Soininen, G van den Dobbelsteen, L Oomen and H Kayhty (2000) Are the enzyme immunoassays for antibodies to pneumococcal capsular polysaccharides serotype specific. Clin Diagn Lab Immunol 7(3), 468-476.
162. X Yu, Y Sun, C Frasch, et al. (1999) Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic. Clin Diagn Lab Immunol 6(4), 519-524.
163. S Romero-Steiner, CE Frasch, G Carlone, et al. (2006) Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol 13(2), 165-169.
164. A Soininen, I Seppala, T Nieminen, et al. (1999) IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines. Vaccine 17(15–16), 1889-1897.
165. M Anttila, M Voutilainen, V Jantti, et al. (1999) Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin Exp Immunol 118(3), 402-407.
166. G Vidarsson, ST Sigurdardottir, T Gudnason, et al. (1998) Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine. Infect Immun 66(6), 2866-2870.
167. M Anttila, J Eskola, H Ahman and H Kayhty (1998) Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis 177(6), 1614-1621.
168. D Goldblatt (1997) Simple solid phase assays for avidity. MW Turner, AP Johnston (Eds) Immunochemistry: A Practical Approach 2nd ed. Oxford: Oxford University Press 31-51.
169. D Goldblatt, L van Etten, FJ van Milligen, et al. (1993) The role of pH in modified ELISA procedures used for the estimation of functional antibody affinity. J Immunol Methods 166(2), 281-285.
170. D Goldblatt, AR Vaz and E Miller (1998) Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 177(4), 1112-1115.
171. RA Macdonald, CS Hosking and CL Jones (1988) The measurement of relative antibody affinity by ELISA using thiocyanate elution. J Immunol Methods 106(2), 191-194.
172. GR Pullen, MG Fitzgerald and CS Hosking (1986) Antibody avidity determination by ELISA using thiocyanate elution. J Immunol Methods 86(1), 83-87.
173. T Wuorimaa, R Dagan, M Vakevainen, et al. (2001) Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J Infect Dis 184(9), 1211-1215.
174. N Ekstrom, H Ahman, J Verho, et al. (2005) Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect Immun 73(1), 369-377.
175. S Romero-Steiner, D Libutti, LB Pais, et al. (1997) Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 4(4), 415-422.
176. JE Martinez, S Romero-Steiner, T Pilishvili, et al. (1999) A flow cytometric opsonophagocytic assay for measurement of functional antibodies elicited after vaccination with the 23-valent pneumococcal polysaccharide vaccine. Clin Diagn Lab Immunol 6(4), 581-586.
177. RA Fleck, S Romero-Steiner and MH Nahm (2005) Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies. Clin Diagn Lab Immunol 12(1), 19-27.
178. SE Johnson, L Rubin, S Romero-Steiner, et al. (1999) Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae. J Infect Dis 180(1), 133-140.
179. E Saeland, G Vidarsson and I Jonsdottir (2000) Pneumococcal pneumonia and bacteremia model in mice for the analysis of protective antibodies. Microb Pathog 29(2), 81-91.
180. S Romero-Steiner, C Frasch, N Concepcion, et al. (2003) Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin Diagn Lab Immunol 10(6), 1019-1024.
181. M Vakevainen, W Jansen, E Saeland, et al. (2001) Are the opsonophagocytic activities of antibodies in infant sera measured by different pneumococcal phagocytosis assays comparable. Clin Diagn Lab Immunol 8(2), 363-369.
182. KT Bieging, G Rajam, P Holder, et al. (2005) Fluorescent multivalent opsonophagocytic assay for measurement of functional antibodies to Streptococcus pneumoniae. Clin Diagn Lab Immunol 12(10), 1238-1242.
183. JE Martinez, EA Clutterbuck, H Li, et al. (2006) Evaluation of multiplex flow cytometric opsonophagocytic assays for determination of functional anticapsular antibodies to Streptococcus pneumoniae. Clin Vaccine Immunol 13(4), 459-466.
184. MH Nahm, DE Briles and X Yu (2000) Development of a multi-specificity opsonophagocytic killing assay. Vaccine 18(24), 2768-2771.
185. KH Kim, J Yu and MH Nahm (2003) Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies. Clin Diagn Lab Immunol 10(4), 616-621.
186. D Bogaert, M Sluijter, R De Groot and PW Hermans (2004) Multiplex opsonophagocytosis assay (MOPA): a useful tool for the monitoring of the 7-valent pneumococcal conjugate vaccine. Vaccine 22(29–30), 4014-4020.
187. T Puumalainen, N Ekstrom, R Zeta-Capeding, et al. (2003) Functional antibodies elicited by an 11-valent diphtheria-tetanus toxoid-conjugated pneumococcal vaccine. J Infect Dis 187(11), 1704-1708.
188. E Bardardottir, S Jonsson, I Jonsdottir, et al. (1990) IgG subclass response and opsonization of Streptococcus pneumoniae after vaccination of healthy adults. J Infect Dis 162(2), 482-488.
189. MH Nahm, JV Olander and M Magyarlaki (1997) Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae. J Infect Dis 176(3), 698-703.
190. RT Coughlin, AC White, CA Anderson, et al. (1998) Characterization of pneumococcal specific antibodies in healthy unvaccinated adults. Vaccine 16(18), 1761-1767.
191. X Yu, B Gray, S Chang, et al. (1999) Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants. J Infect Dis 180(5), 1569-1576.
192. SP Bjarnarson, H Jakobsen, G Del Giudice, et al. (2005) The advantage of mucosal immunization for polysaccharide-specific memory responses in early life. Eur J Immunol 35(4), 1037-1045.
193. A Nurkka, H Ahman, M Yaich, et al. (2001) Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT. Vaccine 20(1–2), 194-201.
194. M Korkeila, H Lehtonen, H Ahman, et al. (2000) Salivary anti-capsular antibodies in infants and children immunised with Streptococcus pneumoniae capsular polysaccharides conjugated to diphtheria or tetanus toxoid. Vaccine 18(13), 1218-1226.
195. Q Zhang and A Finn (2004) Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria. J Clin Pathol 57(10), 1015-1021.
196. Q Zhang, K Arnaoutakis, C Murdoch, et al. (2004) Mucosal immune responses to capsular pneumococcal polysaccharides in immunized preschool children and controls with similar nasal pneumococcal colonization rates. Pediatr Infect Dis J 23(4), 307-313.
197. Q Zhang, E Pettitt, R Burkinshaw, et al. (2002) Mucosal immune responses to meningococcal conjugate polysaccharide vaccines in infants. Pediatr Infect Dis J 21(3), 209-213.
198. T Nieminen, J Eskola and H Kayhty (1998) Pneumococcal conjugate vaccination in adults: circulating antibody secreting cell response and humoral antibody responses in saliva and in serum. Vaccine 16(6), 630-636.
199. T Nieminen, H Kayhty, O Leroy and J Eskola (1999) Pneumococcal conjugate vaccination in toddlers: mucosal antibody response measured as circulating antibody-secreting cells and as salivary antibodies. Pediatr Infect Dis J 18(9), 764-772.
200. T Nieminen, H Kayhty, A Virolainen and J Eskola (1998) Circulating antibody secreting cell response to parenteral pneumococcal vaccines as an indicator of a salivary IgA antibody response. Vaccine 16(2–3), 313-319.
201. C Lue, SJ Prince, A Fattom, et al. (1990) Antibody-secreting peripheral blood lymphocytes induced by immunization with a conjugate consisting of Streptococcus pneumoniae type 12F polysaccharide and diphtheria toxoid. Infect Immun 58(8), 2547-2554.
202. C Lue, A Tarkowski and J Mestecky (1988) Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases of both serum and secretory anti-pneumococcal antibodies. J Immunol 140(11), 3793-3800.
203. C Heilmann and FK Pedersen (1986) Quantitation of blood lymphocytes secreting antibodies to pneumococcal polysaccharides after in vivo antigenic stimulation. Scand J Immunol 23(2), 189-194.
204. A Tarkowski, C Lue, Z Moldoveanu, et al. (1990) Immunization of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgA2-subclass antibody responses. J Immunol 144(10), 3770-3778.
205. M Santosham, JA Englund, P McInnes, et al. (2001) Safety and antibody persistence following Haemophilus influenzae type b conjugate or pneumococcal polysaccharide vaccines given before pregnancy in women of childbearing age and their infants. Pediatr Infect Dis J 20(10), 931-940.
206. KK Kamboj, HL Kirchner, R Kimmel, et al. (2003) Significant variation in serotype-specific immunogenicity of the seven-valent Streptococcus pneumoniae capsular polysaccharide-CRM197 conjugate vaccine occurs despite vigorous T cell help induced by the carrier protein. J Infect Dis 187(10), 1629-1638.
207. T Wuorimaa, H Kayhty, J Eskola, et al. (2001) Activation of cell-mediated immunity following immunization with pneumococcal conjugate or polysaccharide vaccine. Scand J Immunol 53(4), 422-428.
208. H Jakobsen, S Hannesdottir, SP Bjarnarson, et al. (2006) Early life T cell responses to pneumococcal conjugates increase with age and determine the polysaccharide-specific antibody response and protective efficacy. Eur J Immunol 36(2), 287-295.
209. J Eskola, J Ward, R Dagan, et al. (1999) Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 354(9195), 2063-2068.
210. J McVernon, PD Johnson, AJ Pollard, et al. (2003) Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure. Arch Dis Child 88(5), 379-383.
211. DF Kelly, AJ Pollard and ER Moxon (2005) Immunological memory: the role of B cells in long-term protection against invasive bacterial pathogens. JAMA 294(23), 3019-3023.
212. L Jodar, J Butler, G Carlone, et al. (2003) Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 21(23), 3265-3272.
213. EL Anderson, DJ Kennedy, KM Geldmacher, et al. (1996) Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatr 128(5 Pt 1), 649-653.
214. R Dagan, R Melamed, O Zamir and O Leroy (1997) Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. Pediatr Infect Dis J 16(11), 1053-1059.
215. SK Obaro, Z Huo, WA Banya, et al. (1997) A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children. Pediatr Infect Dis J 16(12), 1135-1140.
216. KL O'Brien, MC Steinhoff, K Edwards, et al. (1996) Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines. Pediatr Infect Dis J 15(5), 425-430.
217. H Åhman, H Käyhty, H Lehtonen, et al. (1998) Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr Infect Dis J 17(3), 211-216.
218. H Åhman, H Käyhty, A Vuorela, et al. (1999) Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid. Vaccine 17(20–21), 2726-2732.
219. M Anttila, J Eskola, H Ahman and H Kayhty (1999) Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. Vaccine 17(15–16), 1970-1977.
220. MD Blum, R Dagan, PM Mendelman, et al. (2000) A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers. Vaccine 18(22), 2359-2367.
221. T Kilpi, H Ahman, J Jokinen, et al. (2003) Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis 37(9), 1155-1164.
222. J MacLennan, S Obaro, J Deeks, et al. (2001) Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J Infect Dis 183(1), 97-104.
223. A Nurkka, J Joensuu, I Henckaerts, et al. (2004) Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants. Pediatr Infect Dis J 23(11), 1008-1014.
224. LH Lee, CE Frasch, LA Falk, et al. (2003) Correlates of immunity for pneumococcal conjugate vaccines. Vaccine 21(17–18), 2190-2196.
225. MA Shelly, H Jacoby, GJ Riley, et al. (1997) Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect Immun 65(1), 242-247.
226. DR Feikin, CM Elie, MB Goetz, et al. (2001) Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 20(3–4), 545-553.
227. FP Kroon, JT van Dissel, E Ravensbergen, et al. (2001) Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine 19(7–8), 886-894.
228. CY Chan, DC Molrine, S George, et al. (1996) Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis 173(1), 256-258.
229. S Choo, Q Zhang, L Seymour, et al. (2000) Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants. J Infect Dis 182(4), 1260-1263.
230. A Nurkka, M Lahdenkari, A Palmu and H Kayhty (2004) Salivary antibodies induced by the seven-valent PncCRM conjugate vaccine in the Finnish Otitis Media Vaccine Trial. Vaccine 23(3), 298-304.
231. GS Giebink, M Koskela, PP Vella, et al. (1993) Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: immunogenicity and efficacy in experimental pneumococcal otitis media. J Infect Dis 167(2), 347-355.
232. CJ Lee, RA Lock, PW Andrew, et al. (1994) Protection of infant mice from challenge with Streptococcus pneumoniae type 19F by immunization with a type 19F polysaccharide–pneumolysoid conjugate. Vaccine 12(10), 875-878.
233. JC Paton, RA Lock, CJ Lee, et al. (1991) Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide. Infect Immun 59(7), 2297-2304.
234. CC Peeters, AM Tenbergen-Meekes, JT Poolman, et al. (1992) Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide–protein conjugate vaccine is decreased by admixture of high doses of free saccharide. Vaccine 10(12), 833-840.
235. ME Rodriguez, GP van den Dobbelsteen, LA Oomen, et al. (1998) Immunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response. Vaccine 16(20), 1941-1949.
236. LT van der Ven, GP van den Dobbelsteen, B Nagarajah, et al. (1999) A new rat model of otitis media caused by Streptococcus pneumoniae: conditions and application in immunization protocols. Infect Immun 67(11), 6098-6103.
237. PP Vella, S Marburg, JM Staub, et al. (1992) Immunogenicity of conjugate vaccines consisting of pneumococcal capsular polysaccharide types 6B, 14, 19F and 23F and a meningococcal outer membrane protein complex. Infect Immun 60(12), 4977-4983.
238. DV Madore, N Strong and R Eby (1999) Use of animal testing for evaluating glycoconjugate vaccine immunogenicity. Dev Biol Stand 101 49-56.
239. GS Giebink (1981) The pathogenesis of pneumococcal otitis media in chinchillas and the efficacy of vaccination in prophylaxis. Rev Infect Dis 3(2), 342-353.
240. A Kadioglu, NA Gingles, K Grattan, et al. (2000) Host cellular immune response to pneumococcal lung infection in mice. Infect Immun 68(2), 492-501.
241. R Malley, AM Stack, ML Ferretti, et al. (1998) Anticapsular polysaccharide antibodies and nasopharyngeal colonization with Streptococcus pneumoniae in infant rats. J Infect Dis 178(3), 878-882.
242. DM Musher, B Johnson Jr and DA Watson (1990) Quantitative relationship between anticapsular antibody measured by enzyme-linked immunosorbent assay or radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4. Infect Immun 58(12), 3871-3876.
243. E Saeland, H Jakobsen, G Ingolfsdottir, et al. (2001) Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B. J Infect Dis 183(2), 253-260.
244. AM Stack, R Malley, CM Thompson, et al. (1998) Minimum protective serum concentrations of pneumococcal anti-capsular antibodies in infant rats. J Infect Dis 177(4), 986-990.
245. Warira AW, Scott JAG, Ashton L, et al. The safety and immunogenicity of pneumococcal conjugate vaccine given at birth [abstract SY10.04]. Paper presented at: 5th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 2–6, 2006; Alice Springs, Central Australia.
246. H Käyhty, H Åhman, PR Rönnberg, et al. (1995) Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J Infect Dis 172(5), 1273-1278.
247. A Leach, SJ Ceesay, WA Banya and BM Greenwood (1996) Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants. Pediatr Infect Dis J 15(4), 333-339.
248. MG Lucero, T Puumalainen, JM Ugpo, et al. (2004) Similar antibody concentrations in Filipino infants at age 9 months, after 1 or 3 doses of an adjuvanted, 11-valent pneumococcal diphtheria/tetanus-conjugated vaccine: a randomized controlled trial. J Infect Dis 189(11), 2077-2084.
249. RE Huebner, N Mbelle, B Forrest, et al. (2002) Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa. Pediatr Infect Dis J 21(11), 1004-1007.
250. H Käyhty, H Ahman, K Eriksson, et al. (2005) Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr Infect Dis J 24(2), 108-114.
251. EJ Barzilay, L O'Brien K, YS Kwok, et al. (2006) Could a single dose of pneumococcal conjugate vaccine in children be effective? Modeling the optimal age of vaccination. Vaccine 24(7), 904-913.
252. S Esposito, L Pugni, S Bosis, et al. (2005) Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine 23(14), 1703-1708.
253. Sigurdardottir S, Davidsdottir K, Arason V, et al. Two and three doses of the CRM197 conjugated 9-valent pneumococcal and meningococcal C combination vaccine (9vPnC-MnCC) in infancy, prime for comparable booster responses at 12 months of age [abstract SY10.05]. Paper presented at: 5th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 2–6, 2006; Alice Springs, Central Australia.
254. Goldblatt D. Immunological perspectives on conjugate immunisation–impact on carriage and alternative dosing schedules [abstract SY10.03]. Paper presented at: 5th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 2–6, 2006; Alice Springs, Central Australia.
255. D Goldblatt, J Southern, L Ashton, et al. (2006) Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 25 312-319.
256. HR Shinefield, S Black, P Ray, et al. (1999) Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 18(9), 757-763.
257. H Shinefield, S Black, P Ray, et al. (2002) Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J 21 182-186.
258. TN Saari (2003) Immunization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics 112(1 Pt 1), 193-198.
259. O'Brien KL, Moisi J, Moulton L, et al. Does maternal antibody interfere with the IgG antibody response to pneumococcal conjugate vaccine? [abstract SY4.07]. Paper presented at: 5th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 2–6, 2006; Alice Springs, Central Australia.
260. N Mbelle, RE Huebner, AD Wasas, et al. (1999) Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 180(4), 1171-1176.
261. A Nurkka, H Ahman, M Korkeila, et al. (2001) Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J 20(1), 25-33.
262. MB Rennels, KM Edwards, HL Keyserling, et al. (1998) Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 101(4 Pt 1), 604-611.
263. T Puumalainen, R Dagan, T Wuorimaa, et al. (2003) Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants. Pediatr Infect Dis J 22(2), 141-149.
264. KM Miernyk, AJ Parkinson, KM Rudolph, et al. (2000) Immunogenicity of a heptavalent pneumococcal conjugate vaccine in Apache and Navajo Indian, Alaska native and non-native American children aged <2 years. Clin Infect Dis 31(1), 34-41.
265. B Abraham-Van Parijs (2004) Review of pneumococcal conjugate vaccine in adults: implications on clinical development. Vaccine 22(11–12), 1362-1371.
266. Scott DA, Komjathy SF, Ruckle J, et al. Safety and immunogenicity of the 13-valent penumococcal conjugate vaccine in healthy adults [abstract PO10.21]. Paper presented at: 5th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 2–6, 2006; Alice Springs, Central Australia.
267. MA Shelly, ME Pichichero and JJ Treanor (2001) Low baseline antibody level to diphtheria is associated with poor response to conjugated pneumococcal vaccine in adults. Scand J Infect Dis 33(7), 542-544.
268. HB Konradsen (1995) Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons. Clin Infect Dis 21(3), 616-620.
269. T Wuorimaa, R Dagan, J Eskola, et al. (2001) Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers. Pediatr Infect Dis J 20(3), 272-277.
270. Miernyk K, Bulkow L, Butler J, et al. Immunogenicity of pneumococcal 23-valent polysaccharide adn 7-valent conjugate vaccines used in combination in adults 55–70 years old [abstract PO10.03]. Paper presented at: 5th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 2–6, 2006; Alice Springs, Central Australia.
271. S Jonsson, G Vidarsson, H Valdimarsson, et al. (2002) Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine. Eur Respir J 20(4), 813-818.
272. de Roux A, Schmöle-Tomas B, Ahlers N, et al. Previous pneumococcal polysaccharide vaccine imparts immune response to subsequent pneumococcal conjugate vaccine in the elderly [abstract PO10.11]. Paper presented at: 5th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 2–6, 2006; Alice Springs, Central Australia.
273. de Roux A, Schmöle-Tomas B, Siber G, et al. Opsonophagocytic responses to pneumococcal conjugate vaccine in the elderly [abstract PO6.13]. Paper presented at: 5th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 2–6, 2006; Alice Springs, Central Australia.
274. RU Sorensen, LE Leiva, PA Giangrosso, et al. (1998) Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J 17(8), 685-691.
275. MA Rose, R Schubert, N Strnad and S Zielen (2005) Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine. Clin Diagn Lab Immunol 12(10), 1216-1222.
276. MA Breukels, GT Rijkers, MM Voorhorst-Ogink, et al. (1999) Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta. J Infect Dis 179(5), 1152-1156.
277. Pelton SI, Abzug MJ, Borkowsk W, et al. Functional antibody responses to PCV-PPV regiment in HIV infected children on HAART categorized by entry and nadir CD4 percentage (PACT1024) [abstract PO6.21]. Paper presented at: 5th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 2–6, 2006; Alice Springs, Central Australia.
278. JC King Jr, PE Vink, JJ Farley, et al. (1997) Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection. Pediatrics 99(4), 575-580.
279. VI Spoulou, DL Tsoumas, VG Papaevangelou, et al. (2005) Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children. Vaccine 23(46–47), 5289-5293.
280. SA Madhi, L Kuwanda, C Cutland, et al. (2005) Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J 24(5), 410-416.
281. JC King Jr, PE Vink, JJ Farley, et al. (1996) Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. Pediatr Infect Dis J 15(3), 192-196.
282. G Miiro, H Kayhty, C Watera, et al. (2005) Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. J Infect Dis 192(10), 1801-1805.
283. French N, Kayhty H, Haikala R, et al. Salivary and serum responses to 7-valent pneumococcal conjugate vaccine (PCV) in HIV-infected adults [abstract PO10.23]. Paper presented at: 5th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 2–6, 2006; Alice Springs, Central Australia.
284. Käyhty H, Haikala R, Gordon S, et al. Opsonophagocytic activity of antibodies against Type 6B and 19F Streptococcus pneumoniae after vaccination of HIV-infected Malawian adults with 7-valent pneumococcal conjugate vaccine (PCV) [abstract PO10.30]. Paper presented at: 5th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 2–6, 2006; Alice Springs, Central Australia.
285. M Deloria-Knoll, M Steinhoff, RD Semba, et al. (2006) Effect of zinc and vitamin A Supplementation on antibody responses to a pneumococcal conjugate vaccine in HIV-positive injection drug users: A randomized trial. Vaccine 24(10), 1670-1679.
286. A Stray-Pedersen, IS Aaberge, A Fruh and TG Abrahamsen (2005) Pneumococcal conjugate vaccine followed by pneumococcal polysaccharide vaccine; immunogenicity in patients with ataxia-telangiectasia. Clin Exp Immunol 140(3), 507-516.
287. R Schubert, J Reichenbach, M Rose and S Zielen (2004) Immunogenicity of the seven valent pneumococcal conjugate vaccine in patients with ataxia-telangiectasia. Pediatr Infect Dis J 23(3), 269-270.
288. T Parkkali, H Kayhty, M Anttila, et al. (1999) IgG subclasses and avidity of antibodies to polysaccharide antigens in allogeneic BMT recipients after vaccination with pneumococcal polysaccharide and Haemophilus influenzae type b conjugate vaccines. Bone Marrow Transplant 24(6), 671-678.
289. DC Molrine, JH Antin, EC Guinan, et al. (2003) Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood 101(3), 831-836.
290. JH Antin, EC Guinan, D Avigan, et al. (2005) Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11(3), 213-222.
291. PL Lin, MG Michaels, M Green, et al. (2005) Safety and immunogenicity of the American Academy of Pediatrics–recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients. Pediatrics 116(1), 160-167.
292. D Kumar, C Rotstein, G Miyata, et al. (2003) Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis 187(10), 1639-1645.
293. Ekström N, Grönholm S, Palmu A, The FinOM Study Group, et al. Persistence of anti-pneumococcal (Pnc) polysaccharide (PS) antibodies and avidity 3 to 4 years after immunization with pneumococcal conjugate vaccine PncCRM as measured by 22F EIA. Paper presented at: 4th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); May 9–13, 2004; Helsinki, Finland.
294. Madhi SA, Adrian P, Jassat W, et al. Long term immunogenicity and protection against invasive pneumococcal disease of a conjugate pneumococcal vaccine in HIV infected and HIV uninfected children in the absence of booster dose of vaccine [abstract SY6.07]. Paper presented at: 5th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 2–6, 2006; Alice Springs, Central Australia.
295. PH Makela, H Kayhty, T Leino, et al. (2003) Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine. Vaccine 22(2), 287-292.
296. R Eby (1995) Pneumococcal conjugate vaccines. Pharm Biotechnol 6 695-718.
297. CA Laferriere, RK Sood, JM de Muys, et al. (1998) Streptococcus pneumoniae type 14 polysaccharide-conjugate vaccines: length stabilization of opsonophagocytic conformational polysaccharide epitopes. Infect Immun 66(6), 2441-2446.
298. TL McCool, CV Harding, NS Greenspan and JR Schreiber (1999) B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity. Infect Immun 67(9), 4862-4869.
299. ME Pichichero, S Porcelli, J Treanor and P Anderson (1998) Serum antibody responses of weanling mice and two-year-old children to pneumococcal-type 6A-protein conjugate vaccines of differing saccharide chain lengths. Vaccine 16(1), 83-91.
300. RS Daum, D Hogerman, MB Rennels, et al. (1997) Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. J Infect Dis 176(2), 445-455.
301. MC Steinhoff, K Edwards, H Keyserling, et al. (1994) A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics. Pediatr Infect Dis J 13(5), 368-372.
302. KE Stein (1992) Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 165(Suppl 1), S49-S52.
303. KE Stein (1994) Glycoconjugate vaccines What next. Int J Technol Assess Health Care 10(1), 167-176.
304. A Fattom, YH Cho, C Chu, et al. (1999) Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vaccine 17(2), 126-133.
305. RA Insel (1995) Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. Ann N Y Acad Sci 754 35-47.
306. F Mawas, IM Feavers and MJ Corbel (2000) Serotype of Streptococcus pneumoniae capsular polysaccharide can modify the Th1/Th2 cytokine profile and IgG subclass response to pneumococal-CRM(197) conjugate vaccines in a murine model. Vaccine 19(9–10), 1159-1166.
307. J Eskola, T Kilpi, A Palmu, et al. (2001) Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 344(6), 403-409.
308. H Käyhty and H Åhman (2001) Bridging phase 2 and phase 3 pneumococcal immunologic data for future combination vaccines. Clin Infect Dis 33(Suppl 4), S292-S298.
309. H Åhman, H Käyhty, P Tamminen, et al. (1996) Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. Pediatr Infect Dis J 15(2), 134-139.
310. DM Granoff, SJ Holmes, RB Belshe, et al. (1994) Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants. JAMA 272(14), 1116-1121.
311. S Kurikka (1996) Priming with diphtheria-tetanus-pertussis vaccine enhances the response to the Haemophilus influenzae type b tetanus conjugate vaccine in infancy. Vaccine 14(13), 1239-1242.
312. CC Peeters, AM Tenbergen-Meekes, JT Poolman, et al. (1991) Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect Immun 59(10), 3504-3510.
313. T Barington, L Juul, A Gyhrs and C Heilmann (1994) Heavy-chain isotype patterns of human antibody-secreting cells induced by Haemophilus influenzae type b conjugate vaccines in relation to age and preimmunity. Infect Immun 62(8), 3066-3074.
314. T Barington, M Skettrup, L Juul and C Heilmann (1993) Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components. Infect Immun 61(2), 432-438.
315. TK Wuorimaa, R Dagan, F Bailleux, et al. (2005) Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent pneumococcal conjugate vaccine. Vaccine 23(46–47), 5328-5332.
316. SK Obaro, RA Adegbola, I Chang, et al. (2000) Safety and immunogenicity of a nonavalent pneumococcal vaccine conjugated to CRM197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants. Pediatr Infect Dis J 19(5), 463-469.
317. M Knuf, P Habermehl, C Cimino, et al. (2006) Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine 24(22), 4747-4836.
318. S Choo, L Seymour, R Morris, et al. (2000) Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a Haemophilus influenzae type B conjugate vaccine in United Kingdom infants. Pediatr Infect Dis J 19(9), 854-862.
319. R Dagan, H Kayhty, T Wuorimaa, et al. (2004) Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants. Pediatr Infect Dis J 23(2), 91-98.
320. R Dagan, D Goldblatt, JR Maleckar, et al. (2004) Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. Infect Immun 72(9), 5383-5391.
321. JP Buttery, A Riddell, J McVernon, et al. (2005) Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA 293(14), 1751-1758.
322. P Anderson, J Treanor, S Porcelli and M Pichichero (2003) Non-interference between two protein carriers when used with the same polysaccharide for pneumococcal conjugate vaccines in 2-year-old children. Vaccine 21(13–14), 1554-1559.
323. RM Olander, T Wuorimaa, H Kayhty, et al. (2001) Booster response to the tetanus and diphtheria toxoid carriers of 11-valent pneumococcal conjugate vaccine in adults and toddlers. Vaccine 20(3–4), 336-341.
324. JB Robbins, R Schneerson and SC Szu (1995) Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 171(6), 1387-1398.
325. EA de Velasco, D Merkus, S Anderton, et al. (1995) Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines. Infect Immun 63(3), 961-968.
326. DM Granoff and AH Lucas (1995) Laboratory correlates of protection against Haemophilus influenzae type b disease. Importance of assessment of antibody avidity and immunologic memory. Ann N Y Acad Sci 754 278-288.
327. D Goldblatt, P Richmond, E Millard, et al. (1999) The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus and pertussis vaccine combination. J Infect Dis 180(2), 538-541.
328. AH Lucas and DM Granoff (2001) Imperfect memory and the development of Haemophilus influenzae type B disease. Pediatr Infect Dis J 20(3), 235-239.
329. SB Black, HR Shinefield, J Hansen, et al. (2001) Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 20(12), 1105-1107.
330. S Black, H Shinefield, R Baxter, et al. (2004) Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 23(6), 485-489.
331. KL O'Brien, LH Moulton, R Reid, et al. (2003) Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 362(9381), 355-361.
332. FT Cutts, SM Zaman, G Enwere, et al. (2005) Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365(9465), 1139-1146.
333. Pneumonia Vaccine Trial Invesigators Group (2001) Standardization of interpretations of chest radiographs for the diagnosis of pneumonia in children Geneva: Department of Vaccines and Biologicals, World Health Organzation
334. Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia: Updated analysis using WHO standardized interpretation of chest radiographs. Pediatr Infect Dis Journal. in press.
335. R Dagan, M Sikuler-Cohen, O Zamir, et al. (2001) Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. Pediatr Infect Dis J 20(10), 951-958.
336. SA Madhi and KP Klugman (2004) A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 10(8), 811-813.
337. SA Madhi, H Ludewick, L Kuwanda, et al. (2006) Pneumococcal coinfection with human metapneumovirus. J Infect Dis 193(9), 1236-1243.
338. M Straetemans, A Palmu, K Auranen, et al. (2003) The effect of a pneumococcal conjugate vaccine on the risk of otitis media with effusion at 7 and 24 months of age. Int J Pediatr Otorhinolaryngol 67(11), 1235-1242.
339. E Leibovitz, MR Jacobs and R Dagan (2004) Haemophilus influenzae: a significant pathogen in acute otitis media. Pediatr Infect Dis J 23(12), 1142-1152.
340. JR Casey and ME Pichichero (2004) Changes in frequency and pathogens causing acute otitis media in 1995–2003. Pediatr Infect Dis J 23(9), 824-828.
341. R Dagan, R Melamed, M Muallem, et al. (1996) Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 174(6), 1271-1278.
342. R Dagan, M Muallem, R Melamed, et al. (1997) Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr Infect Dis J 16(11), 1060-1064.
343. R Dagan, N Givon-Lavi, O Zamir, et al. (2002) Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis 185(7), 927-936.
344. F Ghaffar, T Barton, J Lozano, et al. (2004) Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis 39(7), 930-938.
345. From the Centers for Disease Control and Prevention (2002) Updated recommendations on the use of pneumococcal conjugate vaccine in a setting of vaccine shortage—Advisory Committee on Immunization Practices. JAMA 287(7), 833-834.
346. VF Jones, C Harrison, GG Stout and J Hopkins (2005) Nasopharyngeal colonization with heptavalent pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae with prolonged vaccine dosing intervals. Pediatr Infect Dis J 24(11), 969-973.
347. BE Mahon, K Hsu, S Karumuri, et al. (2006) Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine 24(14), 2514-2520.
348. EJ Barzilay, L O'Brien K, YS Kwok, et al. (2005) Could a single dose of pneumococcal conjugate vaccine in children be effective? Modeling the optimal age of vaccination. Vaccine 24(7), 904-913.
349. MZ Capeding, T Puumalainen, CP Gepanayao, et al. (2003) Safety and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein–conjugated pneumococcal vaccine in Filipino infants. BMC Infect Dis 3 17.
350. RP Wise, J Iskander, RD Pratt, et al. (2004) Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine. JAMA 292(14), 1702-1710.
351. W Zhou, V Pool, JK Iskander, et al. (2003) Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)—United States, 1991–2001. MMWR Surveill Summ 52(1), 1-24.
352. J de Aristegui Fernandez, B Cos Arregui, A Zurimendi Carril, et al. (2005) Evaluation of the safety and immunogenicity of pneumococcal seven-valent conjugate vaccine (Prevenar) administered in previously unvaccinated Spanish children aged 24 to 36 months. Vaccine 23(16), 1917-1922.
353. S Zielen, I Buhring, N Strnad, et al. (2000) Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine. Infect Immun 68(3), 1435-1440.
354. T Wuorimaa, H Kayhty, O Leroy and J Eskola (2001) Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults. Vaccine 19(15–16), 1863-1869.
355. ME Pichichero, MA Shelly and JJ Treanor (1997) Evaluation of a pentavalent conjugated pneumococcal vaccine in toddlers. Pediatr Infect Dis J 16(1), 72-74.
356. LA Jackson, KM Neuzil, CG Whitney, et al. (2005) Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 23(28), 3697-3703.
357. S Nachman, S Kim, J King, et al. (2003) Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics 112(1 Pt 1), 66-73.
358. SL Kaplan, EO Mason Jr, ER Wald, et al. (2004) Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 113(3 Pt 1), 443-449.
359. Centers for Disease Control and Prevention (2005) Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease—United States, 1998–2003. MMWR Morb Mortal Wkly Rep 54(36), 893-897.
360. RI Haddy, K Perry, CE Chacko, et al. (2005) Comparison of incidence of invasive Streptococcus pneumoniae disease among children before and after introduction of conjugated pneumococcal vaccine. Pediatr Infect Dis J 24 320-323.
361. K Hsu, S Pelton, S Karumuri, et al. (2005) Massachusetts Department of Public Health Epidemiologists Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr Infect Dis J 24 17-23.
362. S Shafinoori, CC Ginocchio, AJ Greenberg, et al. (2005) Impact of pneumococcal conjugate vaccine and the severity of winter influenza-like illnesses on invasive pneumococcal infections in children and adults. Pediatr Infect Dis J 24 10-16.
363. CL Byington, MH Samore, GJ Stoddard, et al. (2005) Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis 41 21-29.
364. B Flannery, S Schrag, NM Bennett, et al. (2004) Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA 291(18), 2197-2203.
365. TW Hennessy, RJ Singleton, LR Bulkow, et al. (2005) Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity. Vaccine 23 5464-5473.
366. JD Kellner, DL Church, J MacDonald, et al. (2005) Progress in the prevention of pneumococcal infection. CMAJ 173(10), 1149-1151.
367. KA Poehling, BJ Lafleur, PG Szilagyi, et al. (2004) Population-based impact of pneumococcal conjugate vaccine in young children. Pediatrics 114 755-761.
368. KA Poehling, PG Szilagyi, CG Grijalva, et al. (2007) Reduction of frequent otitis media and pressure equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 119(4), 707-715.
369. CG Grijalva, JP Nuorti, PG Arbogast, et al. (2007) Decline in pneumonia hospitalizations following routine childhood immunization with pneumococcal conjugate vaccine in the United States. Lancet 369 1179-1186.
370. KL O'Brien and R Dagan (2003) The potential indirect effect of conjugate pneumococcal vaccines. Vaccine 21 1815-1825.
371. SS Huang, R Platt, SL Rifas-Shiman, et al. (2005) Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 116 e408-e413.
372. MR Moore, TB Hyde, TW Hennessy, et al. (2004) Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska. J Infect Dis 190 2031-2038.
373. CA Lexau, R Lynfield, R Danila, et al. (2005) Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294(16), 2043-2051.
374. AM McBean, Y-T Park, D Caldwell and X Yu (2005) Declining invasive pneumococcal disease in the U.S. elderly. Vaccine 23 5641-5645.
375. KA Poehling, TR Talbot, MR Griffin, et al. (2006) Invasive pneumococcal disease among young infants before and after pneumococcal conjugate vaccine introduction. JAMA In Press.
376. SK Obaro, RA Adegbola, WA Banya and BM Greenwood (1996) Carriage of pneumococci after pneumococcal vaccination. Lancet 348(9022), 271-272.
377. MH Kyaw, R Lynfield, W Schaffner, et al. (2006) Effect of pneumococcal conjugate vaccine introduction on drug-resistant Streptococcus pneumoniae. N Engl J Med 354 1455-1463.
378. T Talbot, K Poehling, R Hartert, et al. (2004) Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 39 641-648.
379. DS Stephens, SM Zughaier, CG Whitney, et al. (2005) Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 855-863.
380. MC McEllistrem, JM Adams, K Patel, et al. (2005) Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 40 1738-1744.
381. AB Brueggemann, DT Griffiths, E Meats, et al. (2003) Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis 187(9), 1424-1432.
382. MC McEllistrem, J Adams, EO Mason and ER Wald (2003) Epidemiology of acute otitis media caused by Streptococcus pneumoniae before and after licensure of the 7-valent pneumococcal protein conjugate vaccine. J Infect Dis 188 1679-1684.
383. CG Whitney, MM Farley, J Hadler, et al. (2003) Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348(18), 1737-1746.
384. R Pai, MR Moore, T Pilishvili, et al. (2005) Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 192 1988-1995.
385. Centers for Disease Control and Prevention (2000) Prevention of pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices. MMWR 49(No. RR-9), 1-35.
386. RS Singleton, TW Hennessy, LR Bulkow, et al. (2007) Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297 1784-1792.
387. PW Roch, VL Krause, M Bartlett, et al. (2006) Invasive pneumococcal disease in Austrilia, 2004. Common Dis Intell 30 80-92.
388. Centers for Disease Control and Prevention (2001) Notice to readers: decreased availability of pneumococcal conjugate vaccine. MMWR 50 783-784.
389. Centers for Disease Control and Prevention (2004) National, state and urban area vaccination coverage among children aged 19–35 months—United States, 2004. MMWR 54 717-721.
390. National Advisory Committee on Immunization (NACI). Statement on recommended use of pneumococcal conjugate vaccine. Canada Communicable Dis Rep 28 1-32.
391. Sante et Services sociaux Q Vaccination provides good protection. November 2004. Online. Available at: http://publications.msss.gouv.qc.ca/acrobat/f/documentation/piq/feuillets_ang/f1.pdf Accessed April 20, 2006, 2006
392. National Health Service Immunisation Information Pneumococcal vaccine added to the childhood immunisation programme; more protection against meningitis and septicaemia. website]. February 8, 2006; Press release. Online. Available at: http://www.immunisation.nhs.uk/newsitem.php?id=56 Accessed April 20, 2006, 2006
393. CG Whitney, T Pilishvili, MM Farley, et al. (2006) Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368 1495-1502.
394. K Mulholland (1999) Strategies for the control of pneumococcal diseases. Vaccine 17 S79-S84.
395. ADIP pneumo Childhood pneumococcal disease: serious, common, preventable. Online Available at: http://www.preventpneumo.org/ Accessed March 4, 2006
396. MM Davis, JL Zimmerman, JR Wheeler and GL Freed (2002) Childhood vaccine purchase costs in the public sector: past trends, future expectations. Am J Public Health 92 1982-1987.
397. Centers for Disease Control and Prevention CDC Vaccine price list. Website]. April 14, 2006; Pediatric/VFC vaccine price list. Available at: http://www.cdc.gov/nip/vfc/cdc_vac_price_list.htm Accessed April 18, 2006
398. TA Lieu, GT Ray, SB Black, et al. (2000) Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 283(11), 1460-1468.
399. GT Ray, CG Whitney, BA Fireman, et al. (2006) Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first five years of use in the United States incorporating herd effects. Pediatr Infect Dis J 25 494-501.
400. H Salo, H Sintonen, JP Nuorti, et al. (2005) Economic evaluation of pneumococcal conjugate vaccination in Finland. Scand J Infect Dis 37 821-832.
401. F Asensi, M De Jose, M Lorente, et al. (2004) A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. Value Health 40 36-51.
402. A Sinha, O Levine, MD Knoll, et al. (2002) Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 369 389-396.
403. JM Peny, O Gleizes and JP Covilard (2005) Financial requirements of immunisation programmes in developing countries: a 2004–2014 perspective. Vaccine 23 4610-4618.
404. F Mawas, J Niggemann, C Jones, et al. (2002) Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197. Infect Immun 70(9), 5107-5114.
405. DJ Lefeber, B Benaissa-Trouw, JF Vliegenthart, et al. (2003) Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3. Infect Immun 71(12), 6915-6920.
406. J Alexander, MF del Guercio, B Frame, et al. (2004) Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE). Vaccine 22(19), 2362-2367.
407. CJ Lee, TR Wang and CE Frasch (2001) Immunogenicity in mice of pneumococcal glycoconjugate vaccines using pneumococcal protein carriers. Vaccine 19(23–24), 3216-3225.
408. H Jakobsen, D Schulz, M Pizza, et al. (1999) Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Infect Immun 67(11), 5892-5897.
409. Oliveira M, Areas A, Campos I, et al. Induction of systemic and mucosal immune response and decrease of Streptococcus pneumoniae colonization by nasal innoculation of mice with recombinant lactic acid bacteria expressing the Pneumococcal Surface Antigen A [abstract SY11.07]. Paper presented at: 5th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 2–6, 2006; Alice Springs, Central Australia.
410. LS McDaniel, J Yother, M Vijayakumar, et al. (1987) Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med 165(2), 381-394.
411. MJ Crain, WD Waltman 2nd, JS Turner, et al. (1990) Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect Immun 58(10), 3293-3299.
412. SK Hollingshead, R Becker and DE Briles (2000) Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 68(10), 5889-5900.
413. A Hakansson, H Roche, S Mirza, et al. (2001) Characterization of binding of human lactoferrin to pneumococcal surface protein A. Infect Immun 69(5), 3372-3381.
414. LS McDaniel, BA Ralph, DO McDaniel and DE Briles (1994) Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. Microb Pathog 17(5), 323-337.
415. DE Briles, RC Tart, E Swiatlo, et al. (1998) Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA). Clin Microbiol Rev 11(4), 645-657.
416. LS McDaniel, JS Sheffield, P Delucchi and DE Briles (1991) PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun 59(1), 222-228.
417. RC Tart, LS McDaniel, BA Ralph and DE Briles (1996) Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J Infect Dis 173(2), 380-386.
418. DE Briles, RC Tart, HY Wu, et al. (1996) Systemic and mucosal protective immunity to pneumococcal surface protein A. Ann N Y Acad Sci 797 118-126.
419. HY Wu, MH Nahm, Y Guo, et al. (1997) Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection and sepsis with Streptococcus pneumoniae. J Infect Dis 175(4), 839-846.
420. TL McCool, TR Cate, G Moy and JN Weiser (2002) The immune response to pneumococcal proteins during experimental human carriage. J Exp Med 195(3), 359-365.
421. DE Briles, SK Hollingshead, J King, et al. (2000) Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 182(6), 1694-1701.
422. EN Miyaji, DM Ferreira, AP Lopes, et al. (2002) Analysis of serum cross-reactivity and cross-protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades. Infect Immun 70(9), 5086-5090.
423. C Rosenow, P Ryan, JN Weiser, et al. (1997) Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol Microbiol 25(5), 819-829.
424. S Hammerschmidt, SR Talay, P Brandtzaeg and GS Chhatwal (1997) SpsA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component. Mol Microbiol 25(6), 1113-1124.
425. Q Cheng, D Finkel and MK Hostetter (2000) Novel purification scheme and functions for a C3-binding protein from Streptococcus pneumoniae. Biochemistry 39(18), 5450-5457.
426. R Janulczyk, F Iannelli, AG Sjoholm, et al. (2000) Hic, a novel surface protein of Streptococcus pneumoniae that interferes with complement function. J Biol Chem 275(47), 37257-37263.
427. S Dave, A Brooks-Walter, MK Pangburn and LS McDaniel (2001) PspC, a pneumococcal surface protein, binds human factor H. Infect Immun 69(5), 3435-3437.
428. Hostetter MK, Cheng Q, Finkel DA. C3-binding protein (pbcA) in Streptococcus pneumoniae: accession number AF067128, abstract: B-478. Paper presented at: The 97th General Meeting of the American Society for Microbiology, 1997.
429. JN Weiser, Z Markiewicz, EI Tuomanen and JH Wani (1996) Relationship between phase variation in colony morphology, intrastrain variation in cell wall physiology and nasopharyngeal colonization by Streptococcus pneumoniae. Infect Immun 64(6), 2240-2245.
430. A Brooks-Walter, DE Briles and SK Hollingshead (1999) The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia. Infect Immun 67(12), 6533-6542.
431. F Iannelli, MR Oggioni and G Pozzi (2002) Allelic variation in the highly polymorphic locus pspC of Streptococcus pneumoniae. Gene 284(1–2), 63-71.
432. M Lipsitch, JK Dykes, SE Johnson, et al. (2000) Competition among Streptococcus pneumoniae for intranasal colonization in a mouse model. Vaccine 18(25), 2895-2901.
433. JS Sampson, SP O'Connor, AR Stinson, et al. (1994) Cloning and nucleotide sequence analysis of psaA, the Streptococcus pneumoniae gene encoding a 37-kilodalton protein homologous to previously reported Streptococcus sp. adhesins. Infect Immun 62(1), 319-324.
434. AM Berry and JC Paton (1996) Sequence heterogeneity of PsaA, a 37-kilodalton putative adhesin essential for virulence of Streptococcus pneumoniae. Infect Immun 64(12), 5255-5262.
435. MC Lawrence, PA Pilling, VC Epa, et al. (1998) The crystal structure of pneumococcal surface antigen PsaA reveals a metal-binding site and a novel structure for a putative ABC-type binding protein. Structure 6(12), 1553-1561.
436. A Dintilhac, G Alloing, C Granadel and JP Claverys (1997) Competence and virulence of Streptococcus pneumoniae: Adc and PsaA mutants exhibit a requirement for Zn and Mn resulting from inactivation of putative ABC metal permeases. Mol Microbiol 25(4), 727-739.
437. R Novak, JS Braun, E Charpentier and E Tuomanen (1998) Penicillin tolerance genes of Streptococcus pneumoniae: the ABC-type manganese permease complex Psa. Mol Microbiol 29(5), 1285-1296.
438. HJ Tseng, AG McEwan, JC Paton and MP Jennings (2002) Virulence of Streptococcus pneumoniae: PsaA mutants are hypersensitive to oxidative stress. Infect Immun 70(3), 1635-1639.
439. DF Talkington, BG Brown, JA Tharpe, et al. (1996) Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin A (PsaA). Microb Pathog 21(1), 17-22.
440. BK De, JS Sampson, EW Ades, et al. (1999) Baculovirus expression, purification and evaluation of recombinant pneumococcal surface adhesin A of Streptococcus pneumoniae. Pathobiology 67(3), 115-122.
441. AD Ogunniyi, RL Folland, DE Briles, et al. (2000) Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun 68(5), 3028-3033.
442. DE Briles, E Ades, JC Paton, et al. (2000) Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun 68(2), 796-800.
443. AM Berry, J Yother, DE Briles, et al. (1989) Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect Immun 57(7), 2037-2042.
444. JC Paton, RA Lock and DJ Hansman (1983) Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae. Infect Immun 40(2), 548-552.
445. RA Lock, D Hansman and JC Paton (1992) Comparative efficacy of autolysin and pneumolysin as immunogens protecting mice against infection by Streptococcus pneumoniae. Microb Pathog 12(2), 137-143.
446. JE Alexander, RA Lock, CC Peeters, et al. (1994) Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun 62(12), 5683-5688.
447. JC Paton and A Ferrante (1983) Inhibition of human polymorphonuclear leukocyte respiratory burst, bactericidal activity and migration by pneumolysin. Infect Immun 41(3), 1212-1216.
448. A Ferrante, B Rowan-Kelly and JC Paton (1984) Inhibition of in vitro human lymphocyte response by the pneumococcal toxin pneumolysin. Infect Immun 46(2), 585-589.
449. C Feldman, TJ Mitchell, PW Andrew, et al. (1990) The effect of Streptococcus pneumoniae pneumolysin on human respiratory epithelium in vitro. Microb Pathog 9(4), 275-284.
450. C Steinfort, R Wilson, T Mitchell, et al. (1989) Effect of Streptococcus pneumoniae on human respiratory epithelium in vitro. Infect Immun 57(7), 2006-2013.
451. CF Rayner, AD Jackson, A Rutman, et al. (1995) Interaction of pneumolysin-sufficient and -eficient isogenic variants of Streptococcus pneumoniae with human respiratory mucosa. Infect Immun 63(2), 442-447.
452. JA Winkelstein (1984) Complement and the host's defense against the pneumococcus. Crit Rev Microbiol 11(3), 187-208.
453. F Michon, PC Fusco, CA Minetti, et al. (1998) Multivalent pneumococcal capsular polysaccharide conjugate vaccines employing genetically detoxified pneumolysin as a carrier protein. Vaccine 16(18), 1732-1741.
454. HC Krivan, DD Roberts and V Ginsburg (1988) Many pulmonary pathogenic bacteria bind specifically to the carbohydrate sequence GalNAc beta 1–4 Gal found in some glycolipids. Proc Natl Acad Sci U S A 85(16), 6157-6161.
455. RT Kelly, S Farmer and D Greiff (1967) Neuraminidase activities of clinical isolates of Diplococcus pneumoniae. J Bacteriol 94(1), 272-273.
456. RD O'Toole, L Goode and C Howe (1971) Neuraminidase activity in bacterial meningitis. J Clin Invest 50(5), 979-985.
457. KL Scanlon, WF Diven and RH Glew (1989) Purification and properties of Streptococcus pneumoniae neuraminidase. Enzyme 41(3), 143-150.
458. B Andersson, J Dahmen, T Frejd, et al. (1983) Identification of an active disaccharide unit of a glycoconjugate receptor for pneumococci attaching to human pharyngeal epithelial cells. J Exp Med 158(2), 559-570.
459. TE Linder, DJ Lim and TF DeMaria (1992) Changes in the structure of the cell surface carbohydrates of the chinchilla tubotympanum following Streptococcus pneumoniae-induced otitis media. Microb Pathog 13(4), 293-303.
460. TE Linder, RL Daniels, DJ Lim and TF DeMaria (1994) Effect of intranasal inoculation of Streptococcus pneumoniae on the structure of the surface carbohydrates of the chinchilla eustachian tube and middle ear mucosa. Microb Pathog 16(6), 435-441.
461. RA Lock, JC Paton and D Hansman (1988) Comparative efficacy of pneumococcal neuraminidase and pneumolysin as immunogens protective against Streptococcus pneumoniae. Microb Pathog 5(6), 461-467.
462. JP Long, HH Tong and TF DeMaria (2004) Immunization with native or recombinant Streptococcus pneumoniae neuraminidase affords protection in the chinchilla otitis media model. Infect Immun 72(7), 4309-4313.
463. Y Zhang, AW Masi, V Barniak, et al. (2001) Recombinant PhpA protein, a unique histidine motif-containing protein from Streptococcus pneumoniae, protects mice against intranasal pneumococcal challenge. Infect Immun 69(6), 3827-3836.
464. JE Adamou, JH Heinrichs, AL Erwin, et al. (2001) Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immun 69(2), 949-958.
465. Hamel J, Charland N, Martin D, Brodeur BR. BVH-3 and BVH-11 pneumococcal protein fragments elicit protective immunity against experimental disease. Paper presented at: 3rd International Symposium on Pneumococci and Pneumococcal Diseases, 2002; Anchorage, Alaska, USA.
466. J Hamel, N Charland, I Pineau, et al. (2004) Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins. Infect Immun 72(5), 2659-2670.
467. SK Obaro, RA Adegbola, JA Tharpe, et al. (2000) Pneumococcal surface adhesin A antibody concentration in serum and nasopharyngeal carriage of Streptococcus pneumoniae in young African infants. Vaccine 19(4–5), 411-412.
468. S Rapola, T Kilpi, M Lahdenkari, et al. (2001) Antibody response to the pneumococcal proteins pneumococcal surface adhesin A and pneumolysin in children with acute otitis media. Pediatr Infect Dis J 20(5), 482-487.
469. B Simell, M Korkeila, H Pursiainen, et al. (2001) Pneumococcal carriage and otitis media induce salivary antibodies to pneumococcal surface adhesin a, pneumolysin and pneumococcal surface protein a in children. J Infect Dis 183(6), 887-896.
470. A Virolainen, J Jero, P Chattopadhyay, et al. (1996) Comparison of serum antibodies to pneumolysin with those to pneumococcal capsular polysaccharides in children with acute otitis media. Pediatr Infect Dis J 15(2), 128-133.
471. A Virolainen, J Jero, H Kayhty, et al. (1995) Antibodies to pneumolysin and pneumococcal capsular polysaccharides in middle ear fluid of children with acute otitis media. Acta Otolaryngol 115(6), 796-803.
472. A Virolainen, W Russell, MJ Crain, et al. (2000) Human antibodies to pneumococcal surface protein A in health and disease. Pediatr Infect Dis J 19(2), 134-138.
473. B Simell, T Kilpi and H Kayhty (2006) Subclass distribution of natural salivary IgA antibodies against pneumococcal capsular polysaccharide of type 14 and pneumococcal surface adhesin A (PsaA) in children. Clin Exp Immunol 143(3), 543-549.
474. Simell B, Melin M, Jaakkola T, et al. Antibodies to PspA families 1 and 2 in saliva but not in serum of children [abstract PO12.02]. Paper presented at: 5th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 2–6, 2006; Alice Springs, Central Australia.
475. E Holmlund, B Quiambao, J Ollgren, et al. (2006) Development of natural antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A and pneumolysin in Filipino pregnant women and their infants in relation to pneumococcal carriage. Vaccine 24(1), 57-65.
476. TL McCool, TR Cate, EI Tuomanen, et al. (2003) Serum immunoglobulin G response to candidate vaccine antigens during experimental human pneumococcal colonization. Infect Immun 71(10), 5724-5732.
477. Q Zhang, J Bernatoniene, L Bagrade, et al. (2006) Serum and mucosal antibody responses to pneumococcal protein antigens in children: relationships with carriage status. Eur J Immunol 36(1), 46-57.
478. GS Nabors, PA Braun, DJ Herrmann, et al. (2000) Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 18(17), 1743-1754.
479. Holmlund E. Serum antibodies to the pneumococcal surface proteins BVH-3 and BVH-11 in Finnish infants and adults. (IMM-26). Paper presented at: 4th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-4), 2004; Helsinki, Finland.
480. MH Kyaw, S Clarke, GF Edwards, et al. (2000) Serotypes/groups distribution and antimicrobial resistance of invasive pneumococcal isolates: implications for vaccine strategies. Epidemiol Infect 125(3), 561-572.
481. D Bogaert, MN Engelen, AJ Timmers-Reker, et al. (2001) Pneumococcal carriage in children in The Netherlands: a molecular epidemiological study. J Clin Microbiol 39(9), 3316-3320.
482. MC Brandileone, AL de Andrade, JL Di Fabio, et al. (2003) Appropriateness of a pneumococcal conjugate vaccine in Brazil: potential impact of age and clinical diagnosis, with emphasis on meningitis. J Infect Dis 187(8), 1206-1212.
483. Lopalco PL, Editorial Team. Use of 7-valent pneumococcal conjugate vaccine in EU. Eurosurveill 11(12), 2006 ( www.eurosurveillance.org/ew/2006/061207.asp) Accessed 11/01/2007.